Assessing the potential role of next generation tyrosine kinase inhibitors in the treatment of cancers with acquired kinase domain mutations

Past few decades have seen the gradual replacement of standard cytotoxic therapy with molecular therapeutics, as the former was associated with significant general cell loss. Although molecular targeted therapies had proven to be highly effective, the duration of treatment efficacy is challenged by the growing resistance of cancer cells. The tyrosine kinase receptors are one of the better explored molecular targets in oncology. Cancer-positive for tyrosine kinase fusion genes has been targeted effectively with tyrosine kinase inhibitors (TKI).

http://ift.tt/2jd4HcM